Table 1.
Demographic and Clinical Characteristics by Microalbuminuria Status
| Characteristic or laboratory value | All (n = 182) | No Microalbuminuria (n = 156) | Microalbuminuria (n = 26) | p-value |
|---|---|---|---|---|
| Age, years | 45 ± 10 | 44 ± 10 | 46 ± 8 | 0.52 |
| Sex, n (%) | 0.15 | |||
| Male | 117 (64.3) | 97 (62.2) | 20 (76.9) | |
| Female | 65 (35.7) | 59 (37.8) | 6 (23.1) | |
| Ethnicity, n (%) | 0.84 | |||
| Caucasian | 56 (30.8) | 49 (31.4) | 7 (26.9) | |
| Black | 107 (58.8) | 91 (58.3) | 16 (61.5) | |
| Asian | 5 (2.7) | 4 (2.6) | 1 (3.9) | |
| Hispanic | 11 (6.0) | 10 (6.4) | 1 (3.9) | |
| Mixed Race | 3 (1.6) | 2 (1.3) | 1 (3.9) | |
| Duration HIV (years) | 14 ± 7 | 13 ± 7.0 | 14 ± 6 | 0.51 |
| HCV-infection, n (%) | 14 (7.7) | 12 (7.7) | 2 (7.7) | 1.00 |
| Smoker, n (%) | 52 (28.6) | 42 (26.9) | 10 (38.5) | 0.23 |
| Tenofovir use, n (%) | 118 (64.8) | 99 (63.5) | 19 (73.1) | 0.34 |
| Ritonavir use, n (%) | 101 (55.5) | 81 (51.9) | 20 (76.9) | 0.02 |
| Lipid Medications, n (%) | 27 (14.8) | 22 (14.1) | 5 (19.2) | 0.50 |
| BMI (kg/m2) | 26.9 ± 6.0 | 27.0 ± 5.7 | 26.3 ± 8.0 | 0.70 |
| Waist-to-Hip Ratio | 0.92 ± 0.07 | 0.92 ± 0.07 | 0.93 ± 0.09 | 0.48 |
| Hypertension, n (%) | 45 (24.7) | 34 (21.8) | 11 (42.3) | 0.02 |
| Metabolic Syndrome, n (%) | 25 (13.7) | 18 (11.5) | 7 (26.9) | 0.03 |
| Systolic blood pressure (mmHg) | 123 ± 14 | 123 ± 14 | 120 ± 14 | 0.25 |
| Diastolic blood pressure (mmHg) | 76 ± 10 | 76 ± 10 | 78 ± 11 | 0.27 |
| Hypertension Medication, n (%) | 41 (22.5) | 31 (19.9) | 10 (38.5) | 0.04 |
| ACE Inhibitors and/or ARB use, n (%) | 19 (10.4) | 13 (8.3) | 6 (23.1) | 0.02 |
HCV, Hepatitis C Virus; BMI, body mass index; ACE, Angiotensin Converting Enzyme; ARB, Angiotensin II Receptor Blocker